Surmodics Announces 2017 Annual Shareholders Meeting
Virtual Meeting on February 14 at 4:00 p.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 9, 2017--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in
vitro diagnostic technologies to the healthcare industry, today
announced that its virtual Annual Meeting of Shareholders will be held
on Tuesday, February 14, at 4:00 p.m. CT (5:00 p.m. ET).
Gary Maharaj, chief executive officer, and Sue Knight, chair of the
board, will provide a brief update on business and key strategic
initiatives underway at the Company.
To attend the meeting, go to www.virtualshareholdermeeting.com/SRDX17
five minutes prior to the start of the meeting to log in. In addition,
the Annual Meeting audio presentation will be archived on the Company’s
website following the meeting.
About Surmodics, Inc.
Surmodics is the global leader in
surface modification technologies for intravascular medical devices and
a leading provider of chemical components for in vitro diagnostic
(IVD) tests and microarrays. Following two recent acquisitions of Creagh
Medical and NorMedix, the Company is executing a key growth strategy for
its medical device business by expanding to offer total intravascular
product solutions to its medical device customers. The combination of
proprietary surface technologies, along with enhanced device design,
development and manufacturing capabilities, enables Surmodics to
significantly increase the value it offers with highly differentiated
intravascular solutions designed and engineered to meet the most
demanding requirements. With this focus on offering total product
solutions, Surmodics’ mission remains to improve the detection and
treatment of disease by using its technology to provide solutions to
difficult medical device and diagnostic challenges. Surmodics is
headquartered in Eden Prairie, Minnesota. For more information about the
company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170209005197/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000